Tekla Capital Management’s Novartis NVS Stock Holding History

Tekla Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$13.7M	Hold	136,225	–	–	0.54%	46
2023 Q1	$12.5M	Hold	136,225	–	–	0.48%	50
2022 Q4	$12.4M	Hold	136,225	–	–	0.47%	51
2022 Q3	$10.4M	Hold	136,225	–	–	0.42%	54
2022 Q2	$11.5M	Hold	136,225	–	–	0.45%	55
2022 Q1	$12M	Hold	136,225	–	–	0.42%	57
2021 Q4	$11.9M	Hold	136,225	–	–	0.38%	60
2021 Q3	$11.1M	Hold	136,225	–	–	0.36%	69
2021 Q2	$12.4M	Hold	136,225	–	–	0.4%	63
2021 Q1	$11.6M	Sell	136,225 -8,300	-6%	-$745K	0.4%	64
2020 Q4	$13.6M	Sell	144,525 -7,000	-5%	-$612K	0.48%	59
2020 Q3	$13.2M	Sell	151,525 -19,483	-11%	-$1.69M	0.49%	49
2020 Q2	$14.9M	Sell	171,008 -8,839	-5%	-$763K	0.57%	40
2020 Q1	$14.8M	Sell	179,847 -31,200	-15%	-$2.78M	0.67%	35
2019 Q4	$20M	Sell	211,047 -38,400	-15%	-$3.45M	0.76%	34
2019 Q3	$21.7M	Sell	249,447 -27,600	-10%	-$2.48M	0.95%	28
2019 Q2	$25.3M	Sell	277,047 -31,914	-10%	-$2.7M	1.03%	24
2019 Q1	$26.6M	Sell	308,961 -16,595	-5%	-$1.33M	1.08%	23
2018 Q4	$25M	Sell	325,556 -34,566	-10%	-$2.69M	1.07%	25
2018 Q3	$27.8M	Buy	360,122 +29,987	+9%	+$2.22M	1.01%	25
2018 Q2	$22.3M	Sell	330,135 -61,603	-16%	-$4.25M	0.85%	34
2018 Q1	$28.4M	Sell	391,738 -34,442	-8%	-$2.62M	1.1%	24
2017 Q4	$32.1M	Sell	426,180 -18,727	-4%	-$1.41M	1.24%	22
2017 Q3	$34.2M	Hold	444,907	–	–	1.22%	22
2017 Q2	$33.3M	Buy	444,907 +167,246	+60%	+$11.9M	1.23%	22
2017 Q1	$18.5M	Hold	277,661	–	–	0.72%	30
2016 Q4	$18.1M	Hold	277,661	–	–	0.77%	30
2016 Q3	$19.6M	Buy	277,661 +87,829	+46%	+$6.4M	0.76%	31
2016 Q2	$14M	Buy	189,832 +86,379	+83%	+$5.97M	0.57%	39
2016 Q1	$6.71M	Hold	103,453	–	–	0.29%	72
2015 Q4	$7.98M	Hold	103,453	–	–	0.29%	72
2015 Q3	$8.52M	Buy	+103,453	New	+$9.21M	0.31%	76

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tekla Capital Management's NVS Position: Q2 2023 in Review

Tekla Capital Management held its Novartis (NVS) position steady in Q2 2023 at 136,225 shares worth $13.7M. The position accounts for 0.54% of the portfolio, ranked #46.

Tekla Capital Management first reported a position in NVS in Q3 2015 and has held it in 32 quarters since. The position peaked at $34.2M in Q3 2017. 1,203 funds tracked by Wall St. Rank hold NVS as of Q2 2023.

Tekla Capital Management held 136,225 shares of Novartis worth $13.7M as of Q2 2023.
Tekla Capital Management left its Novartis share count unchanged in Q2 2023.
Novartis made up 0.54% of Tekla Capital Management's portfolio in Q2 2023, its #46 holding.
Tekla Capital Management first reported a position in Novartis in Q3 2015 and has held it in 32 quarters since.
Tekla Capital Management's Novartis position peaked at $34.2M in Q3 2017.
1,203 funds tracked by Wall St. Rank held Novartis as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.